Shunliban Information Service Co.,Ltd Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Shunliban Information Service Co.,Ltd Stock Forecast and Price Target
Given the average yearlong price target of ¥0.00 provided by prominent analysts over the past few months, there is a potential downside of approximately 0 from the last closing price in July, 2023 for Shunliban Information Service Co.,Ltd's stock if it is reached. This estimation is based on a high estimate of ¥0.00 and a low estimate of ¥0.00. You may be interested in rivals even if you aren't interested in Shunliban Information Service Co.,Ltd stock.
N/A
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥46.16 | Buy/Sell | ¥56.49 | 16.98% |
| T14 Stock Forecast | Tianjin Pharmaceutical Da Ren ... | Outperform |
18
|
$34.99 | Buy/Sell | $1.70 | 30.89% |
| 600436 Stock Forecast | Zhangzhou Pientzehuang Pharmac... | Outperform |
18
|
¥237.24 | Buy/Sell | ¥302.86 | 19.10% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥57.25 | Buy/Sell | ¥65.39 | 11.79% |
| 1093 Stock Forecast | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.71 | Buy/Sell | HK$9.50 | 38.60% |
Shunliban Information Service Co.,Ltd Revenue Forecast for 2023 - 2025 - 2030
Shunliban Information Service Co.,Ltd's Revenue has decreased In the last two years, from ¥774.50M to ¥62.46M – a 91.94% drop. For next year, the 0 analysts predict Revenue of ¥213.87M, which would mean an increase of 242.40%. Over the next eight years, the pros' prediction is Revenueof ¥474.29M, which would mean a eight-year growth forecast of 659.35%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000999 Stock Forecast | China Resources Sanjiu Medical... | Buy |
18
|
¥59.97 | Buy/Sell | ¥65.95 | 13.62% |
| 600085 Stock Forecast | Beijing Tongrentang | Outperform |
16
|
¥42.33 | Buy/Sell | ¥61.18 | 27.57% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.67 | Buy/Sell | ¥33.57 | 20.83% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002294 Stock Forecast | Shenzhen Salubris Pharmaceutic... | Buy |
18
|
¥31.92 | Buy/Sell | ¥35.65 | 15.91% |
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.25 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600518 Stock Forecast | Kangmei Pharmaceutical | - |
6
|
¥1.99 | Buy/Sell | ¥25.97 | -100.00% |
| 300146 Stock Forecast | Byhealth | Outperform |
15
|
¥15.84 | Buy/Sell | ¥26.39 | 29.42% |
| 002262 Stock Forecast | Jiangsu Nhwa Pharmaceutical Co... | Buy |
18
|
¥25.01 | Buy/Sell | ¥31.34 | 23.95% |
Shunliban Information Service Co.,Ltd EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Shunliban Information Service Co.,Ltd's EBITDA has fallen from ¥-102.50M to ¥-50.38M – a 50.85% decrease. For the next year, analysts are expecting EBITDA to reach ¥-95.30M – an increase of 89.16%. Over the next eight years, experts predict that EBITDA will grow by 137.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 900904 Stock Forecast | Shanghai Shenqi Pharmaceutical... | - |
13
|
$6.53 | Buy/Sell | $0.00 | -100.00% |
| 600062 Stock Forecast | China Resources Double-Crane P... | Buy |
16
|
¥21.77 | Buy/Sell | ¥26.00 | 18.24% |
| 600380 Stock Forecast | Joincare Pharmaceutical Group ... | Buy |
18
|
¥11.61 | Buy/Sell | ¥14.72 | 26.79% |
Shunliban Information Service Co.,Ltd EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Shunliban Information Service Co.,Ltd's EBIT has decreased from ¥-108.36M to ¥-56.87M – a 47.52% drop. Next year, analysts are expecting EBIT to reach ¥-102.37M – an increase of 80.01%. Over the next eight years, the forecast is for EBIT to grow by 118.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002773 Stock Forecast | Chengdu Kanghong Pharmaceutica... | Buy |
11
|
¥21.70 | Buy/Sell | ¥24.00 | -100.00% |
| 600867 Stock Forecast | Tonghua Dongbao Pharmaceutical | Buy |
18
|
¥10.09 | Buy/Sell | ¥14.25 | 45.49% |
| 603858 Stock Forecast | Shandong Buchang Pharmaceutica... | - |
18
|
¥16.85 | Buy/Sell | ¥0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 000623 Stock Forecast | Jilin Aodong Pharmaceutical Gr... | Buy |
16
|
¥15.28 | Buy/Sell | ¥0.00 | 48.36% |
| 600422 Stock Forecast | KPC Pharmaceuticals,Inc | Buy |
18
|
¥22.72 | Buy/Sell | ¥28.00 | 10.08% |
| 000766 Stock Forecast | Tonghua Golden-Horse Pharmaceu... | - |
11
|
¥17.16 | Buy/Sell | ¥33.00 | -100.00% |
Site Navigation
.jpg)